Ress Life Investments A/S
2.2.2026 17:05:00 CET | Globenewswire | Press release
Ress Life Investments A/S publishes Net Asset Value (NAV)
Ress Life Investments A/S publishes Net Asset Value (NAV)
Ress Life Investments
Nybrogade 12
DK-1203 Copenhagen K
Denmark
CVR nr. 33593163
www.resslifeinvestments.com
To: Nasdaq Copenhagen
Date: 2 February 2026
Corporate Announcement 05/2026
Ress Life Investments A/S publishes Net Asset Value (NAV).
Ress Life Investments A/S publishes the Net Asset Value (NAV) per share as of 15 January 2026.
NAV per share in USD: 2637.26
The performance during the first half of January is -0.05% in USD. The year-to-date net performance is -0.05% in USD.
Assets under management (AUM) are 210.2 million USD.
The NAV per share in EUR is published on the website of Nasdaq Copenhagen under the section AIF Companies and Funds, where the bid and ask prices are published. The daily NAV in EUR is calculated as the most recently published NAV in USD divided by the European Central Bank’s EUR/USD reference rate on the relevant day.
Questions related to this announcement can be made to the company's AIF-manager, Resscapital AB.
Contact person:
Gustaf Hagerud
gustaf.hagerud@resscapital.com
Tel + 46 73 660 72 42
Note: The terms for subscription of shares, minimum subscription amount and redemption of shares are provided in the Articles of Association, Information Brochure and in the Key Information Document available on the Company's website, www.resslifeinvestments.com.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Sequana Medical NV2.2.2026 18:00:00 CET | Press release
SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
Yacht Club de Monaco2.2.2026 17:31:25 CET | Press release
18th Business Symposium at the Yacht Club de Monaco
Novo Nordisk A/S2.2.2026 16:42:46 CET | Press release
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
Totalkredit A/S2.2.2026 16:02:54 CET | Press release
Correction: Terms for Nykredit's and Totalkredit's auctions - Totalkredit A/S
Totalkredit A/S2.2.2026 16:02:54 CET | Pressemeddelelse
Korrektion: Vilkår for Nykredits og Totalkredits auktioner - Totalkredit A/S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom